Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1994 Feb 1;179(2):541–549. doi: 10.1084/jem.179.2.541

A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides

PMCID: PMC2191365  PMID: 8294865

Abstract

From a human histocompatibility leukocyte antigen (HLA)-DR/DQ hemizygous, B lymphoblastoid progenitor, we isolated a cell line, 10.24.6, with a DR alpha missense mutation (96P-->96S), which results in an N-linked carbohydrate addition at position 94 in the DR alpha 2 domain. Several features of 10.24.6 cells suggest that the mutation disrupts normal intracellular formation of peptide/DR complexes. The mutant HLA-DR dimers, though expressed at the cell surface, lack the conformation of the mature, peptide-loaded class II molecules of the progenitor cell, as assessed by their loss of binding of certain antibodies and by the lack of stability in detergent (sodium dodecyl sulfate) solution. In addition, presentation of endocytosed antigen to HLA-DR-restricted T cells is defective in the mutant, but can be restored by transfection of a wild type DRA gene. Assays with synthetic peptides indicate that the 10.24.6 phenotype is not due to an intrinsic inability of the mutant DR molecules to bind peptides. Therefore, to directly evaluate peptide occupancy of the mutant molecules, we analyzed acid-eluted, HLA-DR-associated peptides. The predominant species from the 10.24.6 mutant is a nested set of invariant chain (Ii)- derived peptides that are undetectable in the DR eluate from progenitor cells. The region of DR alpha altered in the mutant molecules is thus implicated in normal formation of peptide/DR complexes. Further, the same set of Ii peptides associated with the DR molecules is present in the eluate from an antigen presentation mutant with a defect in an major histocompatibility complex (MHC)-linked gene. These results suggest that DR molecules in 10.24.6 and in certain presentation mutants are affected at the same or related steps in class II molecule biosynthesis, raising the possibility that class II molecules interact with an MHC-encoded accessory molecule during antigen presentation.

Full Text

The Full Text of this article is available as a PDF (1.0 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakke O., Dobberstein B. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell. 1990 Nov 16;63(4):707–716. doi: 10.1016/0092-8674(90)90137-4. [DOI] [PubMed] [Google Scholar]
  2. Brown J. H., Jardetzky T., Saper M. A., Samraoui B., Bjorkman P. J., Wiley D. C. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature. 1988 Apr 28;332(6167):845–850. doi: 10.1038/332845a0. [DOI] [PubMed] [Google Scholar]
  3. Cammarota G., Scheirle A., Takacs B., Doran D. M., Knorr R., Bannwarth W., Guardiola J., Sinigaglia F. Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules. Nature. 1992 Apr 30;356(6372):799–801. doi: 10.1038/356799a0. [DOI] [PubMed] [Google Scholar]
  4. Ceman S., Rudersdorf R., Long E. O., Demars R. MHC class II deletion mutant expresses normal levels of transgene encoded class II molecules that have abnormal conformation and impaired antigen presentation ability. J Immunol. 1992 Aug 1;149(3):754–761. [PubMed] [Google Scholar]
  5. Chicz R. M., Urban R. G., Gorga J. C., Vignali D. A., Lane W. S., Strominger J. L. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med. 1993 Jul 1;178(1):27–47. doi: 10.1084/jem.178.1.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cho S. G., Attaya M., Monaco J. J. New class II-like genes in the murine MHC. Nature. 1991 Oct 10;353(6344):573–576. doi: 10.1038/353573a0. [DOI] [PubMed] [Google Scholar]
  7. Cotner T., Mellins E., Johnson A. H., Pious D. Mutations affecting antigen processing impair class II-restricted allorecognition. J Immunol. 1991 Jan 15;146(2):414–417. [PubMed] [Google Scholar]
  8. Demotz S., Matricardi P. M., Irle C., Panina P., Lanzavecchia A., Corradin G. Processing of tetanus toxin by human antigen-presenting cells. Evidence for donor and epitope-specific processing pathways. J Immunol. 1989 Dec 15;143(12):3881–3886. [PubMed] [Google Scholar]
  9. Fuggle S. V., Carter C., Watts F., Kirkley J., Morris P. J. Monoclonal antibody definition of multiple polymorphic epitopes on human leukocyte antigen-DRw52. Hum Immunol. 1987 Nov;20(3):249–264. doi: 10.1016/0198-8859(87)90107-8. [DOI] [PubMed] [Google Scholar]
  10. Geluk A., Bloemhoff W., De Vries R. R., Ottenhoff T. H. Binding of a major T cell epitope of mycobacteria to a specific pocket within HLA-DRw17(DR3) molecules. Eur J Immunol. 1992 Jan;22(1):107–113. doi: 10.1002/eji.1830220117. [DOI] [PubMed] [Google Scholar]
  11. Germain R. N., Hendrix L. R. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature. 1991 Sep 12;353(6340):134–139. doi: 10.1038/353134a0. [DOI] [PubMed] [Google Scholar]
  12. Germain R. N., Rinker A. G., Jr Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Nature. 1993 Jun 24;363(6431):725–728. doi: 10.1038/363725a0. [DOI] [PubMed] [Google Scholar]
  13. Harding C. V., Unanue E. R. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature. 1990 Aug 9;346(6284):574–576. doi: 10.1038/346574a0. [DOI] [PubMed] [Google Scholar]
  14. Karp D. R., Teletski C. L., Jaraquemada D., Maloy W. L., Coligan J. E., Long E. O. Structural requirements for pairing of alpha and beta chains in HLA-DR and HLA-DP molecules. J Exp Med. 1990 Mar 1;171(3):615–628. doi: 10.1084/jem.171.3.615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kittlesen D. J., Brown L. R., Braciale V. L., Sambrook J. P., Gething M. J., Braciale T. J. Presentation of newly synthesized glycoproteins to CD4+ T lymphocytes. An analysis using influenza hemagglutinin transport mutants. J Exp Med. 1993 Apr 1;177(4):1021–1030. doi: 10.1084/jem.177.4.1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kwok W. W., Kovats S., Thurtle P., Nepom G. T. HLA-DQ allelic polymorphisms constrain patterns of class II heterodimer formation. J Immunol. 1993 Mar 15;150(6):2263–2272. [PubMed] [Google Scholar]
  17. König R., Huang L. Y., Germain R. N. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature. 1992 Apr 30;356(6372):796–798. doi: 10.1038/356796a0. [DOI] [PubMed] [Google Scholar]
  18. Lampson L. A., Levy R. Two populations of Ia-like molecules on a human B cell line. J Immunol. 1980 Jul;125(1):293–299. [PubMed] [Google Scholar]
  19. Lotteau V., Teyton L., Peleraux A., Nilsson T., Karlsson L., Schmid S. L., Quaranta V., Peterson P. A. Intracellular transport of class II MHC molecules directed by invariant chain. Nature. 1990 Dec 13;348(6302):600–605. doi: 10.1038/348600a0. [DOI] [PubMed] [Google Scholar]
  20. Malnati M. S., Marti M., LaVaute T., Jaraquemada D., Biddison W., DeMars R., Long E. O. Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells. Nature. 1992 Jun 25;357(6380):702–704. doi: 10.1038/357702a0. [DOI] [PubMed] [Google Scholar]
  21. Marsh S. G., Bodmer J. G. HLA-DR and -DQ epitopes and monoclonal antibody specificity. Immunol Today. 1989 Sep;10(9):305–312. doi: 10.1016/0167-5699(89)90086-8. [DOI] [PubMed] [Google Scholar]
  22. Maurer D., Gorski J. Transfer of polymorphic monoclonal antibody epitopes to the first and second domains of HLA-DR beta-chains by site-directed mutagenesis. J Immunol. 1991 Jan 15;146(2):621–626. [PubMed] [Google Scholar]
  23. Mellins E., Arp B., Singh D., Carreno B., Smith L., Johnson A. H., Pious D. Point mutations define positions in HLA-DR3 molecules that affect antigen presentation. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4785–4789. doi: 10.1073/pnas.87.12.4785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mellins E., Kempin S., Smith L., Monji T., Pious D. A gene required for class II-restricted antigen presentation maps to the major histocompatibility complex. J Exp Med. 1991 Dec 1;174(6):1607–1615. doi: 10.1084/jem.174.6.1607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mellins E., Woelfel M., Pious D. Importance of HLA-DQ and -DP restriction elements in T-cell responses to soluble antigens: mutational analysis. Hum Immunol. 1987 Mar;18(3):211–223. doi: 10.1016/0198-8859(87)90086-3. [DOI] [PubMed] [Google Scholar]
  26. Neefjes J. J., Ploegh H. L. Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistance alpha beta heterodimers in endosomes. EMBO J. 1992 Feb;11(2):411–416. doi: 10.1002/j.1460-2075.1992.tb05069.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Peterson M., Miller J. Antigen presentation enhanced by the alternatively spliced invariant chain gene product p41. Nature. 1992 Jun 18;357(6379):596–598. doi: 10.1038/357596a0. [DOI] [PubMed] [Google Scholar]
  28. Pious D., Dixon L., Levine F., Cotner T., Johnson R. HLA class II regulation and structure. Analysis with HLA-DR3 and HLA-DP point mutants. J Exp Med. 1985 Oct 1;162(4):1193–1207. doi: 10.1084/jem.162.4.1193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Riberdy J. M., Cresswell P. The antigen-processing mutant T2 suggests a role for MHC-linked genes in class II antigen presentation. J Immunol. 1992 Apr 15;148(8):2586–2590. [PubMed] [Google Scholar]
  30. Riberdy J. M., Newcomb J. R., Surman M. J., Barbosa J. A., Cresswell P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature. 1992 Dec 3;360(6403):474–477. doi: 10.1038/360474a0. [DOI] [PubMed] [Google Scholar]
  31. Roche P. A., Cresswell P. Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3150–3154. doi: 10.1073/pnas.88.8.3150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Rudensky AYu, Preston-Hurlburt P., Hong S. C., Barlow A., Janeway C. A., Jr Sequence analysis of peptides bound to MHC class II molecules. Nature. 1991 Oct 17;353(6345):622–627. doi: 10.1038/353622a0. [DOI] [PubMed] [Google Scholar]
  33. Sadegh-Nasseri S., Germain R. N. A role for peptide in determining MHC class II structure. Nature. 1991 Sep 12;353(6340):167–170. doi: 10.1038/353167a0. [DOI] [PubMed] [Google Scholar]
  34. Sant A. J., Braunstein N. S., Germain R. N. Predominant role of amino-terminal sequences in dictating efficiency of class II major histocompatibility complex alpha beta dimer expression. Proc Natl Acad Sci U S A. 1987 Nov;84(22):8065–8069. doi: 10.1073/pnas.84.22.8065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Schamboeck A., Korman A. J., Kamb A., Strominger J. L. Organization of the transcriptional unit of a human class II histocompatibility antigen: HLA-DR heavy chain. Nucleic Acids Res. 1983 Dec 20;11(24):8663–8675. doi: 10.1093/nar/11.24.8663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Sette A., Ceman S., Kubo R. T., Sakaguchi K., Appella E., Hunt D. F., Davis T. A., Michel H., Shabanowitz J., Rudersdorf R. Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. Science. 1992 Dec 11;258(5089):1801–1804. doi: 10.1126/science.1465617. [DOI] [PubMed] [Google Scholar]
  37. Shaw S., Johnson A. H., Shearer G. M. Evidence for a new segregant series of B cell antigens that are encoded in the HLA-D region and that stimulate secondary allogenic proliferative and cytotoxic responses. J Exp Med. 1980 Sep 1;152(3):565–580. doi: 10.1084/jem.152.3.565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Stern L. J., Wiley D. C. The human class II MHC protein HLA-DR1 assembles as empty alpha beta heterodimers in the absence of antigenic peptide. Cell. 1992 Feb 7;68(3):465–477. doi: 10.1016/0092-8674(92)90184-e. [DOI] [PubMed] [Google Scholar]
  39. Stimac E., Urieli-Shoval S., Kempin S., Pious D. Defective HLA DRA X box binding in the class II transactive transcription factor mutant 6.1.6 and in cell lines from class II immunodeficient patients. J Immunol. 1991 Jun 15;146(12):4398–4405. [PubMed] [Google Scholar]
  40. Viville S., Neefjes J., Lotteau V., Dierich A., Lemeur M., Ploegh H., Benoist C., Mathis D. Mice lacking the MHC class II-associated invariant chain. Cell. 1993 Feb 26;72(4):635–648. doi: 10.1016/0092-8674(93)90081-z. [DOI] [PubMed] [Google Scholar]
  41. van Heyningen V., Guy K., Newman R., Steel C. M. Human MHC class II molecules as differentiation markers. Immunogenetics. 1982;16(5):459–469. doi: 10.1007/BF00372104. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES